FreeOx Biotech, a CataloniaBio & HealthTech member, has been granted a patent for its most advanced drug, Ox-01, by the United States Patent and Trademark Office (USPTO). The patent protects the use of Ox-01 until 2038 for patients with ischaemic stroke treated with mechanical thrombectomy.
“This grant is wonderful news for the company as it will allow us to strengthen our drug’s protection in a market representing approximately 50% worldwide in terms of returns and move forward with our regulatory plan with close communication with EMA” said Carlos Lurigados, co-founder and CEO of FreeOx.
Ox-01 is currently in clinical phase III.
Photo: Carlos Lurigados and Dr Ángel Chamorro, recognised expert in stroke, co-founders of FreeOx - © FreeOx Biotech
La mejor actitud que podemos adoptar es la de trat...
The research team observed changes in head circumf...
AtCDF3 gene induced greater production of sugars a...
En nuestro post hablamos sobre este interesante tipo de célula del...
Proceeds to support clinical development of lead first-in-class progra...
Biotechnology portal in Spain
Subscribe to our newsletter and stay up to date with the latest news and deals!
2013 © Biotech-Spain.com - Site Developments SL. All Rights Reserved. Terms of Service | Privacy Policy
Articles
Directory
